Phase 1Recruiting
Renal Impairment Study for Oral EC5026
Assessment of Single Dose Pharmacokinetics of Oral EC5026 in a Population With Chronic Kidney Disease
- Sponsor
- EicOsis Human Health Inc. (Industry)
- Enrollment
- 18 planned
- Conditions
- Chronic Kidney Disease
- Interventions
- EC5026 oral tablet
- Ages
- adults, older adults
- Registry
- NCT07694544
Full record on ClinicalTrials.gov
From the registry
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1. To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function. 2. To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated. Researchers will compare a single 8 mg dose of oral across participants with varying degrees of kidney function impairment (either normal kidney function, or stage 3b chronic kidney disease \[CKD\], or state 4/5 CKD). Participants will be asked to take a single oral dose of EC5026 and will be monitored with PK laboratory assessments and safety assessments (including physical exams, vital signs, electrocardiograms, and others).
Primary outcomes
- Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)
- Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)
- Maximum observed plasma concentration (Cmax)
- Time to the maximum observed concentration of the drug (Tmax)
History
Study completion expected
Primary completion expected
Registered
Started